Smaller doses act differently to larger ones Dr Clare Craig Key points • The same molecule at different doses can produce different effects and sometimes opposite ones. • Regulators expect different efficacy by dose including non-linear dose responses • Safety assessment is built around finding the dose at which harm begins as the dose rises. […]
Tag: Regulatory failure
Pick of the Week – 1st August
The alternative CARE module people’s inquiry; GMC not fit for purpose:
Where did AstraZeneca go?
Update from legal challenge in Netherlands…
The Flawed Assessment of VDPS Claims
The Vaccine Damage Payment Scheme (VDPS) is often portrayed as a financial lifeline for those suffering from vaccine-related injuries. However, upon closer examination, the system appears fundamentally flawed, leaving many without the support they desperately need. Instead of functioning as a proper compensation scheme, the VDPS serves as a temporary measure, intended only to provide interim financial assistance until claimants can pursue legal redress. Given the significant legal barriers and reluctance of courts to hear such cases in the UK, this supposed route to justice remains largely inaccessible.
Yet another Pharmaceutical giant falls foul of the regulations
GlaxoSmithKline fined a mere £5000 for a breach of Pharmaceutical Industry regulations. They join the Hall of Shame
‘Dopesick’: The Long View of Big Pharma
‘Dopesick’ charts the harrowing scandal of OxyContin addiction in the USA, from its origins in Appalachia, one of the first areas identified by the Sackler family of Purdue Pharma to target their new opioid pain relief medication. The Sacklers claimed OxyContin was non-addictive, and aggressively marketed the drug. These claims, couched in the humanitarian discourse of ‘changing attitudes towards pain management’, led to a drastic increase in opioid addiction and drug overdose deaths across the USA. The tragedy was amplified by the complete failure of the FDA to act on evidence about the dangers of OxyContin.
